Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UBX-306
- Development stage
- Preclinical
- Lead developer
- Ubix Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
UBX-306 is a small molecule proteolysis-targeting chimera (PROTAC) currently in the research phase of development by Ubix Therapeutics. It is being developed for applications in immuno-oncology. The drug utilizes Ubix's proprietary Degraducer platform, which involves bifunctional molecules that recruit an E3 ubiquitin ligase to a specific target protein, facilitating its polyubiquitination and subsequent degradation by the 26S proteasome. While the specific biological target of UBX-306 has not been publicly disclosed, the program aims to modulate immune responses against tumors by eliminating key proteins involved in immune evasion or suppression.
02
Targets
MAP4K1 (Hematopoietic progenitor kinase 1)
Beyond the preview
Go deeper on UBX-306.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UBX-306.